[go: up one dir, main page]

WO2003076461A3 - Dimeric tf antagonist comprising two factor vii polypeptides - Google Patents

Dimeric tf antagonist comprising two factor vii polypeptides Download PDF

Info

Publication number
WO2003076461A3
WO2003076461A3 PCT/DK2003/000151 DK0300151W WO03076461A3 WO 2003076461 A3 WO2003076461 A3 WO 2003076461A3 DK 0300151 W DK0300151 W DK 0300151W WO 03076461 A3 WO03076461 A3 WO 03076461A3
Authority
WO
WIPO (PCT)
Prior art keywords
dimeric
antagonist
factor vii
vii polypeptides
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2003/000151
Other languages
French (fr)
Other versions
WO2003076461A2 (en
Inventor
Marianne Kjalke
Palle Jakobsen
Henning Ralf Stennicke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to EP03709668A priority Critical patent/EP1485476A2/en
Priority to AU2003214023A priority patent/AU2003214023A1/en
Priority to JP2003574676A priority patent/JP2005538936A/en
Publication of WO2003076461A2 publication Critical patent/WO2003076461A2/en
Publication of WO2003076461A3 publication Critical patent/WO2003076461A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Optics & Photonics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Dimer FVII polypeptides, which binds and inhibits two TF molecules simultaneously, and thereby functions as an anticoagulant.
PCT/DK2003/000151 2002-03-12 2003-03-12 Dimeric tf antagonist comprising two factor vii polypeptides Ceased WO2003076461A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP03709668A EP1485476A2 (en) 2002-03-12 2003-03-12 Dimeric tf antagonist
AU2003214023A AU2003214023A1 (en) 2002-03-12 2003-03-12 Dimeric tf antagonist comprising two factor vii polypeptides
JP2003574676A JP2005538936A (en) 2002-03-12 2003-03-12 Dimeric TF antagonist

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200200373 2002-03-12
DKPA200200373 2002-03-12

Publications (2)

Publication Number Publication Date
WO2003076461A2 WO2003076461A2 (en) 2003-09-18
WO2003076461A3 true WO2003076461A3 (en) 2004-03-18

Family

ID=27798725

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2003/000151 Ceased WO2003076461A2 (en) 2002-03-12 2003-03-12 Dimeric tf antagonist comprising two factor vii polypeptides

Country Status (4)

Country Link
EP (1) EP1485476A2 (en)
JP (1) JP2005538936A (en)
AU (1) AU2003214023A1 (en)
WO (1) WO2003076461A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20060426A1 (en) 2004-06-02 2006-06-28 Schering Corp TARTARIC ACID DERIVATIVES AS INHIBITORS OF MMPs, ADAMs, TACE AND TNF-alpha
US7638513B2 (en) 2004-06-02 2009-12-29 Schering Corporation Compounds for the treatment of inflammatory disorders
ES2434032T3 (en) * 2005-06-17 2013-12-13 Novo Nordisk Health Care Ag Dimeric and multimeric FVIIA compounds

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010191A1 (en) * 1992-10-30 1994-05-11 Novo Nordisk A/S Low allergenic proteins
WO1994014467A1 (en) * 1992-12-29 1994-07-07 Genentech, Inc. Treatment of inflammatory bowel disease with ifn-gamma inhibitors
US5874407A (en) * 1995-12-04 1999-02-23 Genentech, Inc. Factor VIIA inhibitors
US5932448A (en) * 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
WO2001002439A1 (en) * 1999-07-01 2001-01-11 Yale University Neovascular-targeted immunoconjugates
WO2001021661A1 (en) * 1999-09-20 2001-03-29 Novo Nordisk A/S BIVALENT INHIBITOR OF FVIIa/TF/FXa COMPLEX
WO2002002764A2 (en) * 2000-06-30 2002-01-10 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin k-dependent polypeptides

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932448A (en) * 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
WO1994010191A1 (en) * 1992-10-30 1994-05-11 Novo Nordisk A/S Low allergenic proteins
WO1994014467A1 (en) * 1992-12-29 1994-07-07 Genentech, Inc. Treatment of inflammatory bowel disease with ifn-gamma inhibitors
US5874407A (en) * 1995-12-04 1999-02-23 Genentech, Inc. Factor VIIA inhibitors
WO2001002439A1 (en) * 1999-07-01 2001-01-11 Yale University Neovascular-targeted immunoconjugates
WO2001021661A1 (en) * 1999-09-20 2001-03-29 Novo Nordisk A/S BIVALENT INHIBITOR OF FVIIa/TF/FXa COMPLEX
WO2002002764A2 (en) * 2000-06-30 2002-01-10 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin k-dependent polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DONATE F ET AL: "Dimerization of tissue factor supports solution-phase autoactivation of factor VII without influencing proteolytic activation of factor X.", BIOCHEMISTRY, vol. 39, no. 37, 2000, pages 11467 - 11476, XP002902962 *

Also Published As

Publication number Publication date
WO2003076461A2 (en) 2003-09-18
AU2003214023A1 (en) 2003-09-22
EP1485476A2 (en) 2004-12-15
JP2005538936A (en) 2005-12-22
AU2003214023A8 (en) 2003-09-22

Similar Documents

Publication Publication Date Title
EP1429665A4 (en) Composite staple for completing an anastomosis
EP1578930A4 (en) Cngh0004 polypeptides, antibodies, compositions, methods and uses
WO2006097536A3 (en) Dimeric peptide agonists of the glp-1 receptor
EP2284180A3 (en) Peptides that specifically bind HGF receptor (CMET) and uses thereof
WO2006013202A3 (en) Conjugation of fvii
EA200700210A1 (en) Fc OPTIONS
EP1549679A4 (en) Fusion protein comprising angiopoietin receptor-binding and a multimerization domain
WO2007136893A3 (en) Anti-fgf19 antibodies and methods using same
PL1699822T3 (en) Il-7 fusion proteins with antibody portions, their preparation and their use
EP1786273A4 (en) Sequential protein isolation and purirication schemes by affinity chromatography
WO2004005934A3 (en) Toxicity markers
AU2003225103A1 (en) Bipolar plate assembly having transverse legs
EP1617802A4 (en) Cngh0010 specific polynucleotides, polypeptides, antibodies, compositions, methods and uses.
BR0200820B8 (en) bonding rod in composite.
BR0208469B1 (en) lighter.
WO2005000876A3 (en) Ring finger family proteins and uses related thereto
NO20052422D0 (en) Stabilized solid state polypeptide particles.
WO2004003149A8 (en) Cngh0005 polypeptides, antibodies, compositions, methods and uses
AU2002365269A1 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
WO2003076461A3 (en) Dimeric tf antagonist comprising two factor vii polypeptides
WO2005037236A3 (en) Novel heat shock protein 20-related polypeptides and uses therefor
AU2003237332A1 (en) Anti-relp fusion antibodies, compositions, methods and uses
WO2002079785A3 (en) Phosphoprotein target for insulin and its antagonists
ATE452646T1 (en) COMPOSITIONS WITH EPIGALLOCATECHINGALLATE AND PROTEIN HYDROLYZATE
WO2007053570A3 (en) A polypeptide complex of trpm8 and calmodulin and its uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003709668

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003574676

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003709668

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003709668

Country of ref document: EP